{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:29Z","timestamp":1777876829221,"version":"3.51.4"},"reference-count":54,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and limited therapeutic options, particularly in the metastatic setting. Novel strategies to overcome treatment resistance are highly anticipated and may potentially include the repurposing of existing pharmacologic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To prove the positive effect of angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) on survival in PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted based on Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Web of Science, and Cochrane databases was conducted to identify studies evaluating survival outcomes in patients with PDAC receiving concomitant treatment with ARBs or ACEIs. Survival outcomes were analyzed with random-effects models using hazard ratios (HRs) and 95% confidence intervals (CIs) extracted from included trials. Studies without sufficient survival data were reviewed qualitatively only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 14 studies, comprising a total of 19,287 patients, met the inclusion criteria. Results indicated that the concurrent treatment with ACEIs or ARBs in patients with PDAC was associated with significantly improved overall survival compared to no use (HR\u2009=\u20090.80; 95% CI: 0.76\u20130.86;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The survival benefit associated with the concomitant ACEI\/ARB treatment was observed both in the curative setting (HR\u2009=\u20090.78, 95% CI 0.65\u20130.93,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.007) and the non-curative setting (HR\u2009=\u20090.83, 95% CI 0.76\u20130.90,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Three studies without sufficient survival data for meta-analysis reported other potential benefits associated with the ACEI\/ARB use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our meta-analysis supports the efficacy of renin\u2013angiotensin system inhibitors as concomitant therapy in patients with PDAC. Prospective randomized clinical trials are warranted to validate ACEI\/ARB as adjunctive therapy in well-defined PDAC patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251404266","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:45:22Z","timestamp":1774082722000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of concomitant use of renin\u2013angiotensin system inhibitors on survival in patients with pancreatic ductal adenocarcinoma: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-5993","authenticated-orcid":false,"given":"Leszek","family":"Kraj","sequence":"first","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, Banacha 1a, Warsaw, Poland"},{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Magdalenka, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Chmiel","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Skrobucha","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Grabowska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Szyma\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Magdalenka, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr T.","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Medical University of Gda\u0144sk, Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Peller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1166"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009"},{"issue":"9","key":"e_1_3_4_5_2","first-page":"141","article-title":"Epidemiology and risk factors of pancreatic cancer","volume":"89","author":"Capasso M","year":"2018","unstructured":"Capasso M, Franceschi M, Rodriguez-Castro KI, et al. Epidemiology and risk factors of pancreatic cancer. Acta Biomed 2018; 89(9-s): 141\u2013146.","journal-title":"Acta Biomed"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820962117"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01752-3"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70289"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-488"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13020215"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003301"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i1.262"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2021.04.004"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01364"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/jomfp.JOMFP_136_19"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184504"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1051"},{"key":"e_1_3_4_18_2","volume-title":"Physiology, renin angiotensin system","author":"Fountain JH","year":"2025","unstructured":"Fountain JH, Kaur J, Lappin SL. Physiology, renin angiotensin system. Treasure Island, FL: StatPearls Publishing, 2025."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.07.091"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2005.07.009"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.03.008"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263461"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03080-9"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233945"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05962-5"},{"key":"e_1_3_4_26_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1316"},{"key":"e_1_3_4_29_2","unstructured":"The Cochrane Collaboration. Review Manager (RevMan). London UK: The Cochrane Collaboration 2024."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1873-2"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9972-5"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02311.x"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241247019"},{"issue":"2","key":"e_1_3_4_34_2","first-page":"257","article-title":"Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy","volume":"7","author":"Kasi A","year":"2021","unstructured":"Kasi A, Allen J, Mehta K, et al. Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. J Clin Transl Res 2021; 7(2): 257\u2013262.","journal-title":"J Clin Transl Res"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0892"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-4021-8"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v6.i4.235"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605955"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029532"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0256"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.468"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09200-4"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02777"},{"key":"e_1_3_4_44_2","article-title":"Advancements in systemic therapy for pancreatic cancer","volume":"43","author":"Brown TJ","year":"2023","unstructured":"Brown TJ, Reiss KA, O\u2019Hara MH. Advancements in systemic therapy for pancreatic cancer. Am Soc Clin Oncol Educ Book 2023; 43: e397082.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11823-8"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02478-x"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102353"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.660943"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2014.1002357"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02671-8"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5616"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1177"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031384"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1630"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251404266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251404266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251404266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:56Z","timestamp":1777588436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251404266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["10.1177\/17588359251404266"],"URL":"https:\/\/doi.org\/10.1177\/17588359251404266","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"17588359251404266"}}